A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Adalimumab-Aaty (Adalimumab)

First FDA approval2023-05-23
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$92.8M in CY2024 Part D spend16K claims · 5K beneficiaries · 329 plans surveyed

Lowest NADAC
$495.37/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$767.52
Across all dosage forms in distribution.
Highest NADAC
$913.60
Range is tight.
Plans with PA
490 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Adalimumab-Aaty used for?

Adalimumab-Aaty is a this drug class medication tracked in Medicare Part D.

Is there a generic for Adalimumab-Aaty?

No. Adalimumab-Aaty is brand-only with no generic equivalents currently in market.

How much does my plan pay for Adalimumab-Aaty?

Across 329 Part D plans, Adalimumab-Aaty averages $767.52/unit (NADAC). Lowest available: $495.37/unit. Highest in distribution: $913.60/unit.

Is Adalimumab-Aaty on the FDA shortage list?

No. Adalimumab-Aaty is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Drug class1 alternative in D1
01
Adalimumab
Brand: HUMIRA
$872.45Lowest NADAC
0Generic mfrs
$8.57BCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.